Flash | 15 Jul 2026 10:31:26 ET │ 10 pages Johnson & Johnson (JNJ.N) JNJ Weighs in on Procedural Impacts Jane-Marie Lai +1-212-816-3628 janemarie.lai@citi.com CITI'S TAKE JNJ on its 2Q26 earnings call threw in its hat on the current medtech procedural debate, noting that it sees procedure volumes stable and it does not see evidence of a broad-based demand slow-down. In fact, excluding Cardiovascular (which faced EP competition, and Abiomed clinical headwinds), volumes accelerated in 2Q26 highlighting strong ...